Noxopharm Ltd., of Sydney, reported preclinical results that Veyonda (idronoxil) activates cells associated with both the innate and adaptive immune systems, which increased the number of functional natural killer cells and CD4+ T-helper cells. The company is already testing Veyonda in combination with external beam radiotherapy and intravenous radiopharmaceuticals, but is now considering testing the drug with a checkpoint inhibitor.